T
TSHA
Taysha Gene Therapies, Inc.
4.250
+0.240+5.99%After Hours: 4.230 -0.020 -0.47%19:39 10/27 EDT
OPEN/PREV CLOSE4.030/4.010
TODAY RANGE3.970-4.280
VOL2.82M
MARKET CAP1.38B
52 WEEK RANGE3.455-7.30
AVG VOL (3M)3.56M
% TURNOVER0.69%
TURNOVER--
P/E (TTM)-10.3005
% RANGE7.73%
EPS(TTM)-0.4126
P/E(FORWARD)-8.3333
P/B3.570
BVPS1.191
DIVIDEND--
P/S123.91
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.25B
SHARES OUTSTANDING325.83M
NEXT EARNINGS11/02-11/06
FREE FLOAT293.23M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·10/20 03:32
Taysha Gene Therapies (TSHA) After Early Rett Data With An Undervalued Narrative
Simply Wall St·10/19 02:26
Does Rett Trial Progress Change The Bull Case For Taysha Gene Therapies Stock?
Simply Wall St·10/09 05:32
Taysha Gene Therapies (TSHA) Could Be 66% Undervalued On Rett Syndrome Hopes
TipRanks·09/17 11:20
Taysha Gene Therapies initiated with an Outperform at Wolfe Research
Seeking Alpha·09/11 15:11
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
TipRanks·08/24 00:08
Taysha Gene Therapies Earnings Call Highlights Pivotal Progress
Simply Wall St·08/20 04:45
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA)
Simply Wall St·08/13 21:41
Taysha Gene Therapies (TSHA) Stock Retreats As Cash Burn Deepens
Simply Wall St·08/13 08:30
Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return
TipRanks·08/12 14:35
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)
Same Industry
Name/Symbol
Change%
Price